What Patterns of Tysabri-Related PML Are Reported in Medical Literature?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Specific Drug Safety

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). Understanding the clinical signals and symptom patterns reported in medical literature can help you recognize early warning signs. Building on decades of pharmacovigilance research, this page outlines the reported patterns of PML onset in Tysabri patients and what they mean for monitoring and decision-making.

Tysabri and the Risk of Progressive Multifocal Leukoencephalopathy

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use is associated with a significantly increased risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. PML typically leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The United States Food and Drug Administration requires a boxed warning on the Tysabri label to communicate this risk. Clinical presentation and diagnosis of PML involve progressive neurological deficits such as weakness, visual changes, cognitive decline, and coordination problems. Diagnosis is confirmed by brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. In clinical trials, PML occurred in three patients receiving Tysabri: two among 1869 multiple sclerosis patients treated for a median of 120 weeks (both also received interferon beta-1a), and one among 1043 Crohn's disease patients after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases illustrate the latency between exposure and documented harm, which can range from months to years.

Mechanism and Risk Factors for PML in Tysabri Patients

The mechanistic pathway linking Tysabri to PML involves its pharmacological action. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on immune cells, preventing their migration across the blood-brain barrier. This reduces inflammatory activity in the central nervous system but also impairs immune surveillance against JC virus. In immunocompromised patients, JC virus can reactivate and infect oligodendrocytes, leading to demyelination and the clinical syndrome of PML. Three established risk factors for PML in Tysabri-treated patients are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against expected benefit when initiating or continuing therapy.

Adequacy of Warnings and Legal Considerations

Regarding adequacy of warnings, the Tysabri label includes a boxed warning stating that the drug increases PML risk and that PML usually leads to death or severe disability. It specifies that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML and withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label also notes that Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which aims to ensure informed prescribing and monitoring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, some patients have developed PML and subsequently filed lawsuits alleging inadequate risk communication. Settlement-related considerations for affected patients typically involve evaluating whether the treating physician and patient were adequately informed of PML risk, whether monitoring protocols were followed, and whether earlier detection could have altered outcomes. The timeline between Tysabri exposure and PML diagnosis is critical: longer treatment duration increases risk, and symptoms may emerge insidiously. Patients who develop PML often face catastrophic neurological damage, requiring lifelong care. Legal settlements may address medical expenses, lost income, pain and suffering, and ongoing care needs. Each case is assessed individually based on factors such as duration of therapy, presence of anti-JCV antibodies, prior immunosuppressant use, and adherence to monitoring guidelines.

Summary of Tysabri PML Risk and Litigation Context

In summary, Tysabri carries a well-documented risk of PML, with specific risk factors and a latency period that can extend beyond two years of treatment. The drug's labeling includes prominent warnings and a restricted distribution program, but PML remains a serious adverse event that has led to litigation. Patients and healthcare providers must carefully consider the benefit-risk balance and maintain vigilance for early signs of PML. References https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and why is it associated with PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus, due to its mechanism of blocking immune cell migration into the brain.

What are the settlement criteria for Tysabri PML lawsuits?

Settlement criteria typically include documented Tysabri exposure, confirmed PML diagnosis, evaluation of whether the patient and physician were adequately informed of PML risk, adherence to monitoring protocols, and assessment of factors like treatment duration, anti-JCV antibody status, and prior immunosuppressant use.

How is PML diagnosed in Tysabri patients?

PML diagnosis involves progressive neurological symptoms (weakness, vision changes, cognitive decline), brain MRI showing white matter lesions, and detection of JC virus DNA in cerebrospinal fluid.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.